The sensor will be based on Infineon’s XENSIV radar chipset. Development of the new sensor is expected to be completed by 2021. The new sensor is being developed to target the USD 45 billion market for wearable cardiovascular monitoring devices. It will allow continuous and precise blood pressure measurement without a cuff.
“Bringing together Infineon’s 60 GHz radar chipset and system understanding with Blumio’s expertise in cardiovascular health monitoring in a more formal engagement lets both companies leverage their strengths to more rapidly bring the product to market,” said Adrian Mikolajczak, Head of the Infineon Silicon Valley Innovation Center, Power and Sensor Systems. “We are excited to see our advanced sensors like radar being applied to novel and rapidly expanding health and wellness applications.”
Upon successful completion, a kit combining Infineon’s radar chipset and development board with Blumio’s software and algorithms would be released to consumer and medical wearable device makers to integrate into their blood pressure monitoring devices.
“We are thrilled to work together with Infineon, the technology leader in radar, to jointly bring the new blood pressure sensor to market,” said Catherine Liao, Co-founder and CEO of Blumio. “We have experienced tremendous support since the beginning of our partnership in 2018 and we look forward to further advance our collaboration with Infineon.”
The SVIC was founded as an incubator of new technologies. As well as co-development, the center will also provide funding and resources to support the sensor’s commercialization and provide Blumio with office and laboratory space.
The SVIC is based in Silicon Valley, California and was founded to help foster the area’s startup community and help to bring new technologies to market. Infinen also uses a similar model in Singapore. The Co-Innovation Space help startups in the Asia Pacific region with a year long commitment to provide R&D and manufacturing facilities, as well as access to Infineon research, expertise and guidance.